Recombinant Human Epidermal Growth Factor, Silver Sulfadiazine & Chlorhexidine Gluconate Cream
- Indicated for 1st & 2nd degree burns.
- Can also be used for minor cuts, abrasions, incisions & wounds.
Efficacy of SLVRGEN® in comparison with commercially available Silver sulfadiazine in healthy participants with superficial and partial thickness burn.
|Duration of treatment||SLVRGEN®||Reference|
|1 week||87 (29%)||22 (15%)|
|2 week||213 (71%)||35 (23%)|
|4 week||300 (100%)||89 (59%)|
|6 week||—||150 (100%)|
|1 to 10||5||11|
|11 to 20||11||19|
|20 to 30||23||32|
SLVRGEN® Safety Data
Percentage of adverse events between two treatment groups
The conventional SSD usage delays wound healing process by:1-3
- Absorption of silver from burn wounds leading to cytotoxicity
- Causing bacterial resistance
- Insufficient or delayed production of growth promoting factors and their receptors
Studies show that cytoprotective effect offered by EGF against SSD-exposed cell leads to reversal of impaired wound healing, early cell proliferation & epithelization.1
|Parameters||SLVRGEN®||Silver Sulfadiazine||Colloidal Silver|
|Recombinant human Epidermal Growth Factor + Silver Sulfadiazine + Chlorhexidine Gluconate||Silver Sulfadiazine + Chlorhexidine Gluconate
|Pharmaceutical form||Topical cream||Topical cream||Topical gel|
|Therapeutic indication||Indicated for 1st & 2nd degree burns. Can also be used for minor cuts, abrasions, incisions & wounds.||Burns, wound sepsis, lesions of the skin, wounds & injuries.
|Burns, wounds & ulcers
|Silver content||Silver sulfadiazine 1% w/w||Silver sulfadiazine 1% w/w||Colloidal silver 32 ppm|
|Frequency of application||Reapplied at least every 24 hours||Multiple times a day||Multiple times a day|
|Storage temperature||Stable at room temperature||Stable at room temperature.||Stable at room temperature|
|Observation||The cytotoxic property of SSD in retarding the wound healing can be reversed with the addition of rhEGF.1,4
SLVRGEN® synergistically plays a vital role in controlling infection & also promoting fast wound healing.
|Adsorption of silver from burn wounds leads to impairment of dermal regeneration & decreases the mechanical strength of dermal tissue.1,5
|Silver poisoning is a well-known issue.6|
ppm, parts per million; w/w, weight by weight; As per several studies conducted on rhEGF & SSD.
- Cho Lee, AR, et al. Reversal of silver sulfadiazine-impaired wound healing by epidermal growth factor. Biomaterials. 2005;26(22):4670-4676.
- Hidalgo E. Study of cytotoxicity mechanisms of silver nitrate in human dermal fibroblasts. Toxicol Lett. 1998;98(3):169-179.
- Poon VK. In vitro cytotoxity of silver: implication for clinical wound care. Burns. 2004;30(2):140-147.
- McCauley RL, et al. Cytoprotection of human dermal fibroblasts against silver sulfadiazine using recombinant growth factors. J Surg Res. 1994;56(4):378-84.
- White RJ , et al. Silver Sulphadiazine: A review of the evidence. Wounds UK.
- Niels Hadrup, et al. Oral toxicity of silver ions, silver nanoparticles and colloidal silver – A review. Regul Toxicol Pharmacol. 2014;68(1):1-7